Scientists explored selectively blocking the CYP3A4 protein responsible for breaking down large swaths of approved drugs, providing a way to improve drug efficacy. Scientists at St. Jude Children's ...
—A long-overdue study from Japan focused on the docetaxel-associated development of febrile neutropenia in cancer patients and its association with concomitant polypharmacy involving CYP3A4 inhibitors ...
Cytochrome P450 (CYP) proteins are responsible for breaking down more than 80% of all Food and Drug Administration (FDA)-approved drugs, reducing their effectiveness. However, how to prevent CYPs from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback